Autosomal dominant polycystic kidney disease (ADPKD) is the most common of the monogenic disorders and is characterized by bilateral renal cysts; cysts in other organs including liver, pancreas, spleen, testis and ovary; vascular abnormalities including intracranial aneurysms and subarachnoid hemorrhage; and cardiac disorders such as left ventricular hypertrophy (LVH), mitral valve regurgitation, mitral valve prolapse and aortic regurgitation. Autosomal recessive polycystic kidney disease (ARPKD) is an early-onset multisystem disorder characterized by polycysts divided from the renal collecting ducts, congenital hepatic fibrosis, and ductal plate malformation complicated by pulmonary hyperplasia and systemic hypertension. In these polycystic kidney diseases (PKD), progressive enlargement of the cysts results from the aberrant proliferation of tubule epithelial cells and trans-epithelial fluid secretion leading to extensive nephron loss and interstitial fibrosis. Peroxisome proliferator-activated receptor-γ (PPAR-γ), a member of the liganddependent nuclear receptor superfamily, is expressed in a variety of tissues, including kidneys and liver, and plays important roles in cell proliferation, fibrosis, and inflammation. PPAR-γ agonists ameliorate polycystic kidney, polycystic liver and cardiac defects through β-catenin, c-Myc, CFTR, MCP-1, S6, ERK, and TGF-β signaling pathways in animal models of PKD. In this review, we describe the possible therapeutic value of PPAR-γ agonists in the treatment of renal and hepatic manifestations, and cardiac defects in progressive PKD.
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INTRODUCTION
Polycystic kidney diseases (PKD) are characterized by the progressive enlargement of numerous fluid-filled cysts in both kidneys and include extra renal manifestations [1] . Autosomal dominant PKD (ADPKD) is the most common inherited human renal disease with an incidence of approximately 1:1,000, and is caused by mutations in either PKD1 or PKD2, genes coding for polycystin-1 (PC1) and polycystin-2 (PC2), respectively [2, 3] . The polycystins colocalize at the primary cilia and other cellular sites, and interact with each other and different proteins to form a multifunctional protein complex involved in intracellular calcium (Ca 2+ ) mobility and morphological development in kidneys and other organs [4, 5] . ADPKD is characterized by *Address correspondence to this author at the Education and Research Center of Animal Models for Human Diseases, Fujita Health University, Toyoake, Aichi, 470-1192, Japan; Tel: 81-562-93-2434; Fax: 81-562-93-2649; E-mail: shizun@fujita-hu.ac.jp bilateral renal cysts; cysts in the liver, pancreas, and spleen; frequent hypertension developed prior to the reduction of renal filtration rate; and vascular and cardiac abnormalities such as intracranial aneurysms, subarachnoid hemorrhage, left ventricular hypertrophy (LVH), mitral valve regurgitation, mitral valve prolapse and aortic regurgitation [6, 7] . Autosomal recessive PKD (ARPKD), another type of PKD, is mainly an early-onset, juvenile type multi-system disorder. It is caused by mutations in the polycystic kidney and hepatic disease 1 (PKHD1) gene, which encodes fibrocystin/polyductin (FPC) [8, 9] . FPC interacts with an ADPKD responsible gene, PC2, which possibly regulates the intracellular Ca 2+ concentration and distribution in kidneys, livers, and other organs. ARPKD is characterized by countless fusiform cysts divided from the renal collecting ducts, congenital hepatic fibrosis, and ductal plate malformations complicated by pulmonary hyperplasia and systemic hypertension [10] .
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Fig. (1). Intracellular pathways of (A) normal and (B) PKD cells, and (C) possible effects of PPAR-γ agonist.
In PKD cells, dysfunction of responsible gene products, polycystin-1 (PC1), polycystin-2 (PC2), or fibrocystin/polyductin (FPC) [2, 3, 8, 9] probably decreases intracellular calcium (Ca 2+ ) concentration [5] . A low calcium concentration in the renal or hepatic cell causes proliferation of aberrant cell by up-regulation of cAMP/PKA/B-Raf/MEK/ERK [1, 17, 18, 29, 39] and AKT/mTOR/S6K [39, 80, 81] pathways. In addition, up-regulation of TGF-β causes fibrosis in the kidneys and/or liver [36] [37] [38] [39] . On the other hand, over-expression of MCP-1 results in inflammation of kidneys [51, 52] . Furthermore, up-regulation of CFTR promotes chloride (Cl -) secretion in the kidneys and liver [50, 82, 83] . Based on the reports [39, 47, 50, 51, 63, [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] that PPAR-γ ligands have anti-proliferation and anti-fibrosis effects in the renal and hepatic cancer, it is hypothesized that PPAR-γ agonists inhibit cell proliferation and fibrosis as central pathogenetic features of cyst formation and polycystic kidney and liver progression.
RENAL DISORDERS IN PKD
Since ADPKD is a slow and progressive disorder, it is diagnosed after middle age in most cases. A mutation of the PKD1 gene causes most cases (85%) of ADPKD, whilst the remaining cases (15%) are due to a PKD2 gene mutation [2, 3] . Clinically, PKD1 mutations cause a more severe disease progression than those for PKD2 [6] . End-stage renal disease occurs in approximately one-half of all ADPKD patients, eventually requiring dialysis or kidney transplantation. Hypertension is a major deteriorating factor of ADPKD that causes a decline in renal function and requires proper treatment [11] . Hence, the medical costs of this disease are high, up to two billion dollars in the United States (PKD Foundation, http://www.pkdcure.org/). Renal cyst expansion does not always cause renal insufficiency in progressive PKD. The mean growth ratio of the renal cyst volume is 5.3% per year even in non-azotemic ADPKD patients [12] . The stimulation of cellular proliferation, fluid secretion into the cyst cavity, inflammation, fibrosis and extracellular matrix thickening are major pathological changes in ADPKD. In the case of cellular proliferation mechanisms, stimulation of c-Myc, Jun and Cyclin D1 by the Wnt/β-catenin cascade are also involved in PKD progression [13] [14] [15] [16] . Both the receptor tyrosine kinase cascade and cyclic AMP (cAMP) signaling pathway have roles in the stimulation of tubular cell proliferation to form renal cysts [17, 18] . In normal tubular epithelia, cAMP agonists such as arginine vasopressin (AVP), forskolin and prostaglandin E2 inhibit cell proliferation ( Fig. 1A) , whereas these agonists stimulate the proliferation of cystic epithelial cells through phosphorylation of the Raf/MEK/ERK signaling pathway, one of the mitogen-activated protein (MAP) kinase cascades 
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Hormone Receptor Fig. 1B) . This phenotypic switch response to cAMP agonists is thought to be caused by a reduced intracellular concentration and altered mobility of Ca 2+ by the mutated gene products of PKD1 and PKD2. The PKD1 gene product, PC1, is a cilial sensor of fluid flow inside renal tubules, and signals from PC1 stimulate the PKD2 gene product, PC2, to promote Ca 2+ influx [2, 5, 19] . Defects in this flow sensor system and Ca 2+ release mechanism causes the abnormal biological characteristics of cystic cells. L-type Ca 2+ channel blockers, widely-used as anti-hypertensive agents, stimulate disease progression in a PKD rat model, possibly via cAMPelevating hormones because lowered intracellular Ca 2+ may enhance the stimulatory response to cAMP agonists [20, 21] . Thus, intracellular cAMP lowering agents such as somatostatin analogs [22] [23] [24] and AVP V2 receptor antagonists are included as the possible therapeutic approaches [25] [26] [27] [28] [29] [30] . AVP and other cAMP agonists are also known to stimulate chloride (Cl -) and fluid secretion into the cyst cavity. cAMP-dependent Clsecretion is driven by the cystic fibrosis transmembrane conductance regulator (CFTR) channel located in apical membrane [31, 32] . Hence, antagonists of cAMP signaling cascade may be effective in reducing fluid-filled cyst expansion. Interstitial fibrosis is known to reduce nephron numbers and cause deterioration in renal function. In ADPKD kidneys, fibrotic areas overexpressing α-smooth muscle actin and vimentin and showing upregulation of transforming growth factor-β1 (TGF-β1)/Smad2/3 signaling are observed [33] [34] [35] [36] [37] . Stimulation of TGF-β1 expression is also seen in fibro-cystic kidneys in orthologous animal models of ARPKD [38, 39] . Hence, trials designed to downregulate the TGF-β signaling cascade may help to maintain certain numbers of functioning nephrons.
CYSTIC AND FIBROTIC CHANGES IN OTHER ORGANS
In ADPKD, cysts often arise also in the liver (94%), pancreas (40%) and other organs such as the spleen [40] . Polycystic liver disease complicated by ADPKD and resulting in dyspnea, abdominal pain and distention occurs at a relatively high rate in multiparous women [41] . Liver cysts originate from bile duct cholangiocytes and estrogen is thought to be a stimulating factor in their formation [42] . Congenital hepatic fibrosis is a typical pathological phenomenon in fibro-cystic livers in ARPKD patients [10] . Cystic and fibrotic disease in the liver has also been demonstrated in animal models of PKD rats, Pkd2 ws25/mice, BALB/C-cpk mice and PCK rats [38, 39, [42] [43] [44] .
CARDIOVASCULAR DISORDERS
Hereditary PKD is a systemic syndrome known to be complicated by hypertension, cardiovascular complications, LVH, aneurysms and cardiac valvular abnormalities [7, 11, 45] . Hypertension is an early manifestation of PKD and is a risk factor for chronic renal failure and cardiovascular disorders. Since the renin-angiotensin-aldosterone system (RAAS) is thought to have critical roles in the onset of hypertension, early treatment for high blood pressure is recommended in such cases [46] . One of the cardiovascular complications of ADPKD, LVH, is a major cause of death in these patients [45] . In addition, because the activation of RAAS is involved in LVH, effective anti-hypertensive agents may help to reduce risk factors for cardiovascular mortality. Similar to human patients, complications that occur in animal models of PKD include hemorrhagic pericardial effusion and double-outlet right ventricle (DORV) in Pkd1 -/mice, and hypertension, ventricular septum absence, and ventricular septal and atrial septal defect in Pkd2 -/mice [47, 48] .
ANIMAL MODELS OF PKD
There are several transgenic and spontaneous animal models of human PKD. In Pkd1 -/mice, numerous renal cysts with a decreased expression of β-catenin and c-Myc are observed in the bilateral kidneys, and hemorrhagic pericardial effusion and DORV are found in the embryonic heart [47] (Table 1A ). In PC-Pkd1-KO mice, countless cysts in both kidneys and increased levels of blood urea nitrogen are observed [49] . In Pkd2 -/mice, glomerular and tubular cysts are observed in the bilateral kidneys at E16.5, and defects in the heart, loss of the ventricular septum, and both ventricular and atrial septal defects are seen after E13.5 [48] . In spontaneous rat models of PKD, bilateral polycystic kidneys and a polycystic liver with an elevated fibrosis index, enhanced cell proliferation, increased activity of the MAP kinase and AKT/mammalian target of rapamycin (mTOR)/ribosomal S6 protein (S6) pathways, and overexpression of TGF-β and CFTR are observed [39, 50] ( Table 1B) . In another rat model, Han:SPRD Cy, increased expression of β-catenin, TGF-β, monocyte chemoattractant protein-1 (MCP-1), and osteopontin (OPN) with extracellular matrix thickening and monocyte infiltration of the kidneys is observed [51, 52] (Table 1C ). In both spontaneous rat models of PKD and Han:SPRD Cy, the blood pressure gradually increases and may deteriorate renal and vascular disorders [our unpublished data, 51].
PPAR-γ AGONISTS AND THEIR POSSIBLE EFFECTS UPON PKD-ASSOCIATED RENAL, HEPATIC AND CARDIOVASCULAR DISORDERS
Peroxisome proliferator-activated receptors (PPARs) belong to a nuclear receptor superfamily of ligand-activated transcription factors, which contains subtypes α, β/δ, and γ. PPAR-γ is activated by fatty acids and is widely expressed in several organs including the kidney and liver [53] [54] [55] [56] . Polaris is known to localize to the primary cilia discovered in Oak Ridge polycystic kidney mouse, and PPAR-γ transcriptional factor mRNA was decreased by siRNA against polaris in cultured mesenchymal stem cells [57] . Anti-diabetic thiazolidinediones, troglitazone, pioglitazone, ciglitazone and rosiglitazone are known to control blood sugar levels in diabetic patients. These PPAR-γ agonists regulate the cell cycle and inhibit fibrosis, infiltration and metastasis of cancer cells, and also inflammation and the modulation of cytokines as non-metabolic effects (Fig.  1C) . Thiazolidinediones are used for clinical trials in diabetic nephropathy patients [58] , and ameliorating effects in renal disorders are reported from animal models of obesity [59, Table 1 Effects of PPAR-γ agonists in animal models of PKD. 60] , glomerulonephritis, and glomerulosclerosis [61, 62] . One of these agonists, trogilitazone, inhibits the growth of pancreatic cancer cells by blocking ERK, a key enzyme that mediates renal/hepatic cystic cell proliferation during the onset of PKD [63] . PPAR-γ agonists modulate numerous effectors of the extracellular matrix, a major component of renal and hepatic cyst formation, and of cardiac and endothelial disorders in PKD [64, 65] . PPAR-γ agonists inhibit renal fibrosis and inflammation as well as hepatic regeneration that is characteristic of PKD [66, 67] , possibly by inhibiting TGF-β1 activity and increasing the expression of bone morphogenic protein-7, a potential anti-fibrotic factor [68] [69] [70] [71] . AKT/mTOR/S6 signaling, thought to play critical roles in PKD progression, is known to be suppressed by the PPAR-γ agonist, pioglitazone [39] (Fig. 1C) . Furthermore, the PPAR agonists, pioglitazone and rosiglitazone, have been reported to decrease the inflammatory cytokines, IL-1, IL-6, iNOS and tumor necrosis factor-α through the inhibiting activity of activator protein-1, STAT, and nuclear factor-κB, which are considered to be stimulators of interstitial inflammation in renal, hepatic and cardiac tissues [72] [73] [74] [75] [76] [77] [78] .
A: Mouse models with Pkd1 gene knockout
Characterizations Effects of PPAR-γ agonists Name
We have observed in our laboratory that a 16 week treatment with pioglitazone (10 mg/kg/day) reduced polycystic kidney and liver disease progression in PCK rats, an orthologous model of human ARPKD. In hepatic cholangiocytes and mTOR signaling in renal epithelia, this is accomplished possibly by targeting ERK, a downstream kinase of Raf/MEK, which is activated by either receptor tyrosine kinase agonists or cAMP agonists. [39] (Table 1B , Fig. 1C )． In addition, we observed in our previous study that pioglitazone displayed anti-fibrotic and antiinflammatory effects in a fibro-cystic liver with decreased TGF-β1 expression in PCK [39] (Table 1B, Fig. 1C) . The mRNA expression level of PPAR-γ was decreased by pioglitazone in whole kidney specimens in this rat model [our unpublished data]. Muto et al. [47] have previously determined the effects of pioglitazone in an ADPKD mouse model with a Pkd1 mutation (Table 1A, Fig. 1C) . Treatment of pregnant female mice with pioglitazone (80 mg/kg/day) from E7.5-9.5 improved the survival of the Pkd1 −/− embryo (which reached E18.5) and ameliorated cardiac defects and renal cystogenesis. Long term (six months) treatment of adult Pkd1 +/− mice with pioglitazone (40 mg/kg/day) has also been shown to improve endothelial function [47] (Table 1A , Fig. 1C) . Raphael et al. have also reported that pioglitazone (4.8 mg/kg/day) increased the survival rate in an ADPKD model in which Pkd1 was knocked out [79] (Table 1A, Fig.  1C) . Intriguingly, in this model, pioglitazone had no effect on renal cyst formation but a lowered blood pressure suggesting an antihypertensive effect. Rosiglitazone, another PPAR-γ agonist, was demonstrated to reduce renal cystic disease progression, including a decrease in TGF-β1, MCP-1 and β-catenin levels, and also decreased blood pressure and prolonged the life span of Han:SPRD Cy rats [51] (Table  1C , Fig. 1C) .
CONCLUSION
PPAR-γ agonists have been shown to inhibit PKD progression associated with cardiovascular disorders in animal models by blocking the signaling cascades that mediate pathological changes in various tissues and organs. The use of PPAR-γ agonists as therapeutic agents deserve therefore to be considered as potentially useful in the treatment of polycystic kidney, polycystic liver and cardiovascular disorders in PKD patients.
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